{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T21:36:40Z","timestamp":1740173800393,"version":"3.37.3"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T00:00:00Z","timestamp":1549584000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Chiesi Limited"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Prim Care Resp Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Co-prescription of Aerochamber<jats:sup>\u00ae<\/jats:sup> spacer with non-extrafine beclometasone diproprionate (non-EF BDP) is common but unlicensed. We report a comparison of inhaled corticosteroid (ICS)-related adverse events between patients co-prescribed Aerochamber compared to the licensed Volumatic<jats:sup>\u00ae<\/jats:sup> spacer. We utilised two historical cohorts: questionnaire-based and electronic medical record (EMR)-based, to assess patient-reported and EMR-recorded adverse events in patients with asthma prescribed non-EF BDP. Marginal effect estimate (MEE) was calculated to determine non-inferiority of Aerochamber compared to Volumatic in terms of patient-reported oral thrush and hoarseness with margin of 0.13. Other patient-reported adverse events (sore throat, bruising, weight gain, and coughing), and EMR-recorded adverse events were also assessed. Rate of patient-reported oral adverse events were non-inferior in 385 patients prescribed Aerochamber compared to 155 patients prescribed Volumatic (27.7 vs 29.9%; MEE, \u22120.043; 95% CI, \u22120.133 to 0.047). Total patient-reported adverse events did not differ significantly between Aerochamber and Volumatic (53.3 vs 49.7% with \u22651 adverse event). The EMR-based study of 1471 matched pairs of subjects did not show significantly different number of EMR-recorded adverse events between Aerochamber and Volumatic (12.5 vs 12.8% with \u22651 adverse events). Co-prescribing Aerochamber with non-EF BDP does not increase the risk for patient-reported and EMR-recorded ICS-related adverse events compared to co-prescribing Volumatic.<\/jats:p>","DOI":"10.1038\/s41533-019-0115-0","type":"journal-article","created":{"date-parts":[[2019,2,8]],"date-time":"2019-02-08T13:55:25Z","timestamp":1549634125000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Comparison of adverse events associated with different spacers used with non-extrafine beclometasone dipropionate for asthma"],"prefix":"10.1038","volume":"29","author":[{"given":"Simon Wan Yau","family":"Ming","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Haughney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4115-7376","authenticated-orcid":false,"given":"Dermot","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shishir","family":"Patel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Ochel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina Stagno","family":"d\u2019Alcontres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susannah","family":"Thornhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2760-0693","authenticated-orcid":false,"given":"Janwillem W. H.","family":"Kocks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9728-9992","authenticated-orcid":false,"given":"David","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,8]]},"reference":[{"key":"115_CR1","unstructured":"Global Initiative for Asthma. 2017 GINA Report, Global Strategy for Asthma Management and Prevention. https:\/\/ginasthma.org\/wp-content\/uploads\/2016\/01\/wms-GINA-2017-main-report-tracked-changes-for-archive.pdf (2018)."},{"key":"115_CR2","unstructured":"National Heart, Lung, and Blood Institute, National Asthma Education and Prevention Program. Expert Panel Report 3: Guidelines for the Diagnosis and Management of Asthma. Report No. 3, NIH Publication Number 08-5846 (NIH, Bethesda, 2007)."},{"key":"115_CR3","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1164\/ajrccm.157.3.157315","volume":"157","author":"PJ Barnes","year":"1998","unstructured":"Barnes, P. J., Pedersen, S. & Busse, W. W. Efficacy and safety of inhaled corticosteroids. New developments. Am. J. Respir. Crit. Care Med. 157, S1\u201353 (1998).","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"115_CR4","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1056\/NEJM200008033430504","volume":"343","author":"S Suissa","year":"2000","unstructured":"Suissa, S., Ernst, P., Benayoun, S., Baltzan, M. & Cai, B. Low-dose inhaled corticosteroids and the prevention of death from asthma. N. Engl. J. Med. 343, 332\u2013336 (2000).","journal-title":"N. Engl. J. Med."},{"key":"115_CR5","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jaci.2011.09.011","volume":"128","author":"LK Williams","year":"2011","unstructured":"Williams, L. K. et al. Quantifying the proportion of severe asthma exacerbations attributable to inhaled corticosteroid nonadherence. J. Allergy Clin. Immunol. 128, 1185\u20131191 (2011). e1182.","journal-title":"J. Allergy Clin. Immunol."},{"key":"115_CR6","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.rmed.2016.09.015","volume":"120","author":"PNR Dekhuijzen","year":"2016","unstructured":"Dekhuijzen, P. N. R. et al. Incidence of oral thrush in patients with COPD prescribed inhaled corticosteroids: effect of drug, dose, and device. Respir. Med. 120, 54\u201363 (2016).","journal-title":"Respir. Med."},{"key":"115_CR7","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1034\/j.1398-9995.2001.00100.x","volume":"56","author":"JC Dubus","year":"2001","unstructured":"Dubus, J. C. et al. Local side-effects of inhaled corticosteroids in asthmatic children: influence of drug, dose, age, and device. Allergy 56, 944\u2013948 (2001).","journal-title":"Allergy"},{"key":"115_CR8","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1001\/archinte.159.9.941","volume":"159","author":"BJ Lipworth","year":"1999","unstructured":"Lipworth, B. J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis. Arch. Intern. Med. 159, 941\u2013955 (1999).","journal-title":"Arch. Intern. Med."},{"key":"115_CR9","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1590\/S1806-37132013000400003","volume":"39","author":"CR Pinto","year":"2013","unstructured":"Pinto, C. R. et al. Local adverse effects associated with the use of inhaled corticosteroids in patients with moderate or severe asthma. J. Bras. Pneumol. 39, 409\u2013417 (2013).","journal-title":"J. Bras. Pneumol."},{"key":"115_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1177\/0091270004271094","volume":"45","author":"K Richter","year":"2005","unstructured":"Richter, K., Kanniess, F., Biberger, C., Nave, R. & Magnussen, H. Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J. Clin. Pharmacol. 45, 146\u2013152 (2005).","journal-title":"J. Clin. Pharmacol."},{"key":"115_CR11","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1111\/j.1398-9995.2006.01090.x","volume":"61","author":"R Buhl","year":"2006","unstructured":"Buhl, R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 61, 518\u2013526 (2006).","journal-title":"Allergy"},{"key":"115_CR12","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.rmed.2005.11.029","volume":"100","author":"JM Foster","year":"2006","unstructured":"Foster, J. M. et al. Higher patient perceived side effects related to higher daily doses of inhaled corticosteroids in the community: a cross-sectional analysis. Respir. Med. 100, 1318\u20131336 (2006).","journal-title":"Respir. Med."},{"key":"115_CR13","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1378\/chest.126.1.213","volume":"126","author":"NJ Roland","year":"2004","unstructured":"Roland, N. J., Bhalla, R. K. & Earis, J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 126, 213\u2013219 (2004).","journal-title":"Chest"},{"key":"115_CR14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.5694\/j.1326-5377.2003.tb05167.x","volume":"178","author":"H Powell","year":"2003","unstructured":"Powell, H. & Gibson, P. G. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J. Aust. 178, 223\u2013225 (2003).","journal-title":"Med J. Aust."},{"key":"115_CR15","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1016\/j.rmed.2013.03.009","volume":"107","author":"D Price","year":"2013","unstructured":"Price, D. et al. Real-life comparison of beclometasone dipropionate as an extrafine- or larger-particle formulation for asthma. Respir. Med. 107, 987\u20131000 (2013).","journal-title":"Respir. Med."},{"key":"115_CR16","doi-asserted-by":"publisher","first-page":"359","DOI":"10.2500\/aap.2016.37.3983","volume":"37","author":"NJ Amar","year":"2016","unstructured":"Amar, N. J., Moss, M. H., Kerwin, E. M., Li, J. & Small, C. J. Safety and efficacy of beclomethasone dipropionate delivered by breath-actuated or metered-dose inhaler for persistent asthma. Allergy Asthma Proc. 37, 359\u2013369 (2016).","journal-title":"Allergy Asthma Proc."},{"key":"115_CR17","doi-asserted-by":"publisher","first-page":"960","DOI":"10.1136\/thx.41.12.960","volume":"41","author":"MJ Smith","year":"1986","unstructured":"Smith, M. J. & Hodson, M. E. Twice daily beclomethasone dipropionate administered with a concentrated aerosol inhaler: efficacy and patient compliance. Thorax 41, 960\u2013963 (1986).","journal-title":"Thorax"},{"key":"115_CR18","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1136\/adc.61.8.788","volume":"61","author":"NJ Shaw","year":"1986","unstructured":"Shaw, N. J. & Edmunds, A. T. Inhaled beclomethasone and oral candidiasis. Arch. Dis. Child 61, 788\u2013790 (1986).","journal-title":"Arch. Dis. Child"},{"key":"115_CR19","doi-asserted-by":"publisher","first-page":"354","DOI":"10.2500\/aap.2017.38.4078","volume":"38","author":"M Vandewalker","year":"2017","unstructured":"Vandewalker, M., Hickey, L. & Small, C. J. Efficacy and safety of beclomethasone dipropionate breath-actuated or metered-dose inhaler in pediatric patients with asthma. Allergy Asthma Proc. 38, 354\u2013364 (2017).","journal-title":"Allergy Asthma Proc."},{"key":"115_CR20","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1034\/j.1601-0825.2001.70402.x","volume":"7","author":"AN Ellepola","year":"2001","unstructured":"Ellepola, A. N. & Samaranayake, L. P. Inhalational and topical steroids, and oral candidosis: a mini review. Oral. Dis. 7, 211\u2013216 (2001).","journal-title":"Oral. Dis."},{"key":"115_CR21","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1093\/infdis\/123.4.371","volume":"123","author":"L Knight","year":"1971","unstructured":"Knight, L. & Fletcher, J. Growth of Candida albicans in saliva: stimulation by glucose associated with antibiotics, corticosteroids, and diabetes mellitus. J. Infect. Dis. 123, 371\u2013377 (1971).","journal-title":"J. Infect. Dis."},{"key":"115_CR22","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1081-1206(10)61870-4","volume":"90","author":"C Fukushima","year":"2003","unstructured":"Fukushima, C. et al. Oral candidiasis associated with inhaled corticosteroid use: comparison of fluticasone and beclomethasone. Ann. Allergy Asthma Immunol. 90, 646\u2013651 (2003).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"115_CR23","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/S1081-1206(10)60711-9","volume":"98","author":"GS Rachelefsky","year":"2007","unstructured":"Rachelefsky, G. S., Liao, Y. & Faruqi, R. Impact of inhaled corticosteroid-induced oropharyngeal adverse events: results from a meta-analysis. Ann. Allergy Asthma Immunol. 98, 225\u2013238 (2007).","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"115_CR24","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s40264-013-0029-7","volume":"36","author":"JF van Boven","year":"2013","unstructured":"van Boven, J. F., de Jong-van den Berg, L. T. & Vegter, S. Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf. 36, 231\u2013236 (2013).","journal-title":"Drug Saf."},{"key":"115_CR25","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/0091-6749(80)90200-6","volume":"65","author":"JH Toogood","year":"1980","unstructured":"Toogood, J. H., Jennings, B., Greenway, R. W. & Chuang, L. Candidiasis and dysphonia complicating beclomethasone treatment of asthma. J. Allergy Clin. Immunol. 65, 145\u2013153 (1980).","journal-title":"J. Allergy Clin. Immunol."},{"key":"115_CR26","unstructured":"National Institute for Health and Care Excellence. Asthma. https:\/\/www.nice.org.uk\/guidance\/qs25\/chapter\/Quality-statements (2017)."},{"key":"115_CR27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0021-8502(82)90002-7","volume":"13","author":"DCorr Dolovich","year":"1982","unstructured":"Dolovich, D. Corr, McCormack, M., Ruffin, R., Obminski, G. & Newhouse, M. Design and characteristics of a portable breath actuated, particle size selective medical aerosol inhaler. J. Aerosol Sci. 13, 1\u20137 (1982).","journal-title":"J. Aerosol Sci."},{"key":"115_CR28","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1378\/chest.127.1.335","volume":"127","author":"MB Dolovich","year":"2005","unstructured":"Dolovich, M. B. et al. Device selection and outcomes of aerosol therapy: evidence-based guidelines: American College of Chest Physicians\/American College of Asthma, Allergy, and Immunology. Chest 127, 335\u2013371 (2005).","journal-title":"Chest"},{"key":"115_CR29","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1183\/09031936.00166410","volume":"37","author":"BL Laube","year":"2011","unstructured":"Laube, B. L. et al. What the pulmonary specialist should know about the new inhalation therapies. Eur. Respir. J. 37, 1308\u20131331 (2011).","journal-title":"Eur. Respir. J."},{"key":"115_CR30","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/0091-6749(88)90911-6","volume":"81","author":"GA Salzman","year":"1988","unstructured":"Salzman, G. A. & Pyszczynski, D. R. Oropharyngeal candidiasis in patients treated with beclomethasone dipropionate delivered by metered-dose inhaler alone and with Aerochamber. J. Allergy Clin. Immunol. 81, 424\u2013428 (1988).","journal-title":"J. Allergy Clin. Immunol."},{"key":"115_CR31","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1164\/arrd.1984.129.5.723","volume":"129","author":"JH Toogood","year":"1984","unstructured":"Toogood, J. H., Baskerville, J., Jennings, B., Lefcoe, N. M. & Johansson, S. A. Use of spacers to facilitate inhaled corticosteroid treatment of asthma. Am. Rev. Respir. Dis. 129, 723\u2013729 (1984).","journal-title":"Am. Rev. Respir. Dis."},{"key":"115_CR32","unstructured":"Emc+. Clenil Modulite 50, 100, 200, 250 micrograms inhaler. https:\/\/www.medicines.org.uk\/emc\/medicine\/21018 (2017)."},{"key":"115_CR33","first-page":"17008","volume":"27","author":"W Yau","year":"2017","unstructured":"Yau, W. et al. Examining licensed and unlicensed spacer use with nonextrafine beclometasone dipropionate treatment in a real-life patient population with asthma in the United Kingdom. NPJ Prim. Care Respir. Med. 27, 17008 (2017).","journal-title":"NPJ Prim. Care Respir. Med."},{"key":"115_CR34","first-page":"CD002160","volume":"1","author":"B Mash","year":"2001","unstructured":"Mash, B., Bheekie, A. & Jones, P. W. Inhaled vs oral steroids for adults with chronic asthma. Cochrane Database Syst. Rev. 1, CD002160 (2001).","journal-title":"Cochrane Database Syst. Rev."},{"key":"115_CR35","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1046\/j.1365-2125.1999.00900.x","volume":"47","author":"PW Barry","year":"1999","unstructured":"Barry, P. W. & O\u2019Callaghan, C. A comparative analysis of the particle size output of beclomethasone diproprionate, salmeterol xinafoate and fluticasone propionate metered dose inhalers used with the Babyhaler, Volumatic and Aerochamber spacer devices. Br. J. Clin. Pharmacol. 47, 357\u2013360 (1999).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"115_CR36","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1183\/09031936.04.00015404","volume":"23","author":"GW t Jong","year":"2004","unstructured":"t Jong, G. W., Eland, I. A., Sturkenboom, M. C., van den Anker, J. N. & Strickerf, B. H. Unlicensed and off-label prescription of respiratory drugs to children. Eur. Respir. J. 23, 310\u2013313 (2004).","journal-title":"Eur. Respir. J."},{"key":"115_CR37","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1016\/j.jaip.2017.01.004","volume":"5","author":"DB Price","year":"2017","unstructured":"Price, D. B. et al. Inhaler errors in the CRITIKAL study: type, frequency, and association with asthma outcomes. J. Allergy Clin. Immunol. Pract. 5, 1071\u20131081 (2017). e1079.","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"115_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.3109\/02770903.2013.854379","volume":"51","author":"M Reznik","year":"2014","unstructured":"Reznik, M., Silver, E. J. & Cao, Y. Evaluation of MDI-spacer utilization and technique in caregivers of urban minority children with persistent asthma. J. Asthma 51, 149\u2013154 (2014).","journal-title":"J. Asthma"},{"key":"115_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2017-000189","volume":"4","author":"A Crespo-Lessmann","year":"2017","unstructured":"Crespo-Lessmann, A., Plaza, V., Gonzalez-Barcala, F. J., Fernandez-Sanchez, T. & Sastre, J. Concordance of opinions between patients and physicians and their relationship with symptomatic control and future risk in patients with moderate-severe asthma. BMJ Open Respir. Res. 4, e000189 (2017).","journal-title":"BMJ Open Respir. Res."},{"key":"115_CR40","doi-asserted-by":"publisher","first-page":"S92","DOI":"10.1513\/AnnalsATS.201308-276RM","volume":"11","author":"D Price","year":"2014","unstructured":"Price, D. et al. Complementing the randomized controlled trial evidence base. Evolution not revolution. Ann. Am. Thorac. Soc. 11, S92\u201398 (2014).","journal-title":"Ann. Am. Thorac. Soc."},{"key":"115_CR41","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1016\/S2213-2600(13)70199-1","volume":"1","author":"N Roche","year":"2013","unstructured":"Roche, N. et al. Integrating real-life studies in the global therapeutic research framework. Lancet Respir. Med. 1, e29\u201330 (2013).","journal-title":"Lancet Respir. Med."},{"key":"115_CR42","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1378\/chest.113.3.587","volume":"113","author":"LP Boulet","year":"1998","unstructured":"Boulet, L. P. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 113, 587\u2013592 (1998).","journal-title":"Chest"},{"key":"115_CR43","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.jaip.2016.03.007","volume":"4","author":"JF van Boven","year":"2016","unstructured":"van Boven, J. F. et al. Enhancing respiratory medication adherence: the role of health care professionals and cost-effectiveness considerations. J. Allergy Clin. Immunol. Pract. 4, 835\u2013846 (2016).","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"115_CR44","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.socscimed.2004.01.019","volume":"59","author":"N Britten","year":"2004","unstructured":"Britten, N., Stevenson, F., Gafaranga, J., Barry, C. & Bradley, C. The expression of aversion to medicines in general practice consultations. Soc. Sci. Med. 59, 1495\u20131503 (2004).","journal-title":"Soc. Sci. Med."},{"key":"115_CR45","doi-asserted-by":"publisher","first-page":"439","DOI":"10.4104\/pcrj.2013.00088","volume":"22","author":"D Price","year":"2013","unstructured":"Price, D. et al. Clinical and cost effectiveness of switching asthma patients from fluticasone-salmeterol to extra-fine particle beclometasone-formoterol: a retrospective matched observational study of real-world patients. Prim. Care Respir. 22, 439\u2013448 (2013).","journal-title":"Prim. Care Respir."},{"key":"115_CR46","unstructured":"OPCRD. The Optimum Patient Care Research Database (OPCRD), https:\/\/opcrd.co.uk\/ (2016)."},{"key":"115_CR47","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1136\/amiajnl-2013-001847","volume":"21","author":"AR Tate","year":"2014","unstructured":"Tate, A. R. et al. Exploiting the potential of large databases of electronic health records for research using rapid search algorithms and an intuitive query interface. J. Am. Med Inform. Assoc. 21, 292\u2013298 (2014).","journal-title":"J. Am. Med Inform. Assoc."},{"key":"115_CR48","doi-asserted-by":"publisher","first-page":"15026","DOI":"10.1038\/npjpcrm.2015.26","volume":"25","author":"V Cooper","year":"2015","unstructured":"Cooper, V. et al. Patient-reported side effects, concerns and adherence to corticosteroid treatment for asthma, and comparison with physician estimates of side-effect prevalence: a UK-wide, cross-sectional study. NPJ Prim. Care Respir. Med. 25, 15026 (2015).","journal-title":"NPJ Prim. Care Respir. Med"}],"container-title":["npj Primary Care Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0115-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0115-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T02:54:22Z","timestamp":1671245662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41533-019-0115-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["115"],"URL":"https:\/\/doi.org\/10.1038\/s41533-019-0115-0","relation":{},"ISSN":["2055-1010"],"issn-type":[{"type":"electronic","value":"2055-1010"}],"subject":[],"published":{"date-parts":[[2019,2,8]]},"assertion":[{"value":"29 March 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 February 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"D.P. has board membership with Aerocrine, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, Mylan, Mundipharma, Napp, Novartis, Regeneron Pharmaceuticals, Sanofi Genzyme, Teva Pharmaceuticals; consultancy agreements with Almirall, Amgen, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Mylan, Mundipharma, Napp, Novartis, Pfizer, Teva Pharmaceuticals, Theravance; grants and unrestricted funding for investigator-initiated studies (conducted through Observational and Pragmatic Research Institute Pte Ltd) from Aerocrine, AKL Research and Development Ltd, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Mylan, Mundipharma, Napp, Novartis, Pfizer, Regeneron Pharmaceuticals, Respiratory Effectiveness Group, Sanofi Genzyme, Teva Pharmaceuticals, Theravance, UK National Health Service, Zentiva (Sanofi Generics); payment for lectures\/speaking engagements from Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, Cipla, GlaxoSmithKline, Kyorin, Mylan, Merck, Mundipharma, Novartis, Pfizer, Regeneron Pharmaceuticals, Sanofi Genzyme, Skyepharma, Teva Pharmaceuticals; payment for manuscript preparation from Mundipharma, Teva Pharmaceuticals; payment for the development of educational materials from Mundipharma, Novartis; payment for travel\/accommodation\/meeting expenses from Aerocrine, AstraZeneca, Boehringer Ingelheim, Mundipharma, Napp, Novartis, Teva Pharmaceuticals; funding for patient enrolment or completion of research from Chiesi, Novartis, Teva Pharmaceuticals, Zentiva (Sanofi Generics); stock\/stock options from AKL Research and Development Ltd which produces phytopharmaceuticals; owns 74% of the social enterprise Optimum Patient Care Ltd (Australia and UK) and 74% of Observational and Pragmatic Research Institute Pte Ltd (Singapore); and is peer reviewer for grant committees of the Efficacy and Mechanism Evaluation programme, and Health Technology Assessment. D.R. has received support to attend meetings, delivered educational events on behalf of or provided consultancy to: AZ, Chiesi, TEVA, Trudel Medical, Novartis, BI, Optimum Patient Care, MEDA\/Mylan, Stallergenes. J.W.H.K. reports grants and personal fees from AstraZeneca, grants and personal fees from Boehringer Ingelheim, grants from Chiesi, grants and personal fees from GSK, grants and personal fees from Novartis, grants from Mundi Pharma, grants from TEVA, outside the submitted work. J.H. reports grants and research supports from Boehringer Ingelheim, GSK, and Teva; and Honoria or consultation fees from AZ, Boehringer Ingelheim, Cipla, Chiesi, Mundipharma, Novartis, Pfizer, Sanofi, and Teva. S.P. and M.O. are employed by Chiesi, the sponsor of the study. S.W.Y.M., M.S.d\u2019.A., and S.T. are past employees of the Observational and Pragmatic Research Institute, which has conducted paid research in respiratory disease on behalf of the following organisations in the past 5 years: Anaxys, AstraZeneca, Boehringer Ingelheim, British Lung Foundation, Chiesi, Circassia (formerly Aerocrine), GlaxoSmithKline, Harvey Walsh, Mapi, Morningside Healthcare, Mundipharma, Mylan (formerly Meda), Napp, Novartis, Orion, Plymouth University, Regeneron, Respiratory Effectiveness Group, Roche, Sanofi, Takeda, Teva, University of East Anglia, Zentiva (a Sanofi company).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}